Arena Pharmaceuticals, Inc. Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 16 of 24 Posts
1 2
Biotech Stocks Emerge Unscathed And Ready To Go
Article By: Tarun Chandra, CFA Friday, May 18, 2018 8:41 PM EST
The biotech stocks have been demonstrating strong resilience in the face of intense volatility since February and, remarkably, keeping pace with the broader indexes, considering the highly speculative and volatile nature of the group.
In this article: CVS, MRK, IBB, INCY, ESRX, XBI, ARNA, ECYT, IMMU, IRWD, DVAX, SUPN, SRPT, AGIO, QURE, HRTX, LOXO, ATRA, BGNE, ADAP, CRSP, CBIO, GTHX, MRTX
Read
Arena Pharmaceuticals Jumps After Ulcerative Colitis Trial Hits Targets
Article By: The Fly Tuesday, March 20, 2018 12:26 PM EST
Shares of Arena Pharmaceuticals are on the rise after the company said its ulcerative colitis drug met its primary, secondary, and clinical remission endpoints in a Phase 2 trial.
In this article: ARNA Also: CELG
Read
Arena Pharmaceuticals Upgraded To Outperform From Market Perform At Wells Fargo
Article By: The Fly Wednesday, January 3, 2018 8:16 AM EST
Wells Fargo analyst Jim Birchenough upgraded Arena Pharmaceuticals to Outperform and raised his price target for the shares to $53 from $19.
In this article: ARNA Also: CELG
Read
Week In Review: China Life Science Deals Total $550 Million
Article By: ChinaBio® Today Saturday, December 9, 2017 4:13 PM EST
Pfizer (NYSE: PFE​) signed a $226 million agreement for China/Asian rights to Cresemba® (isavuconazole), an antifungal drug and Everest Medicines announced a $224 million partnership with San Diego's Arena Pharma.
In this article: JNJ, GNBT, BYSI, BMY, ARNA, BABA, PFE
Read
E Small Caps - Long Term Consistent Outperformance
Article By: Tarun Chandra, CFA Friday, November 10, 2017 6:35 PM EST
Small cap stocks represent a segment that has consistently outperformed the larger caps over the long term. A portfolio should consider a stable and long-term allocation towards this segment.
In this article: KEM, KRO, WTW, ARNA, OSTK, QQQ, WPRT, DVAX, INSM, IWM, CHGG, ABEO, MRTX, GDS
Read
Biotech Investing Guide: 3 Stocks To Buy And 3 To Avoid
Article By: Arpita Dutt Friday, March 11, 2016 2:10 PM EST
Anyone interested in biotech stocks will know that it could be challenging to pick winners in this industry which is constantly growing and changing. We have zeroed in on 3 biotech stocks to buy and 3 to avoid.
In this article: ARNA, MNTA, REGN, AMGN, CELG, GILD Also: ABBV
Read
E Arena Pharmaceuticals Announces Collaboration With Privately Held Boehringer Ingelheim
Article By: Terry Chrisomalis Tuesday, January 12, 2016 6:37 PM EST
Arena stands to make more than $250 million in milestone payments.
In this article: ARNA
Read
Arena Pharmaceuticals 1Q Loss Narrower-Than-Expected
Article By: Zacks Investment Research Tuesday, May 12, 2015 6:27 AM EST
Arena Pharmaceuticals, Inc. (ARNA) reported a first-quarter 2015 loss of 10 cents per share, narrower than the Zacks Consensus Estimate of a loss of 14 cents and the year-ago loss of 12 cents.
In this article: ARNA, ESALY Also: GILD, ALIOF
Read
Strongest Stocks On StockTwits Last Week
Article By: Blair Jensen Thursday, March 19, 2015 1:42 PM EST
Over the past week here are the stocks with the most bullish messages from the StockTwits community.
In this article: AMRN, TWTR, DIS, REGN, V, ORCL, ARNA, SBUX, FDX, MS, WFC, GM
Read
Shares Of Orexigen Soar After It Announces Improved Safety Results For Weight-Loss Drug
Article By: Terry Chrisomalis Tuesday, March 3, 2015 2:37 PM EST
Orexigen's drug Contrave shows not only shows great safety but also shows the ability to reduce heart-related problems as compared to placebo.
In this article: OREX, ARNA, VVUS
Read
T2108 Update – Finally A Convergence Of (Tentative) Warning Signs
Article By: Dr. Duru Thursday, February 26, 2015 2:58 AM EST
The volatility index, the VIX, made a strong move upward from its low of the day. The candlestick looks like a hammer bottom in the making.
In this article: UVXY, AXP, MCD, Z, VIX, TEX, ARNA, AMBA, AAPL, SPY
Read
E Shares Of Arena Pharmaceuticals Soar 65% After Early Positive Results In Autoimmune Diseases
Article By: Terry Chrisomalis Wednesday, January 7, 2015 2:24 PM EST
Drug shows promise in decreasing lymphocyte count.
In this article: ARNA, ESALF
Read
E Novo Nordisk's Saxenda Approved But Company Enters Into A Crowded Obesity Market
Article By: Terry Chrisomalis Friday, December 26, 2014 3:58 PM EST
Saxenda Approved by the FDA to treat Obesity but faces big obstacles against many competitors.
In this article: NVO, TKPHF, OREX, ARNA, VVUS
Read
Arena Pharmaceuticals Posts In Line Q3 Loss, Belviq Grows
Article By: Zacks Investment Research Tuesday, November 4, 2014 11:41 AM EST
Arena Pharma recorded third-quarter revenues of $8.2 million, below the Zacks Consensus Estimate of $10 million.
In this article: ARNA
Read
E Small Cap Best And Worst Report - September 18, 2014
Article By: E.B. Capital Markets Thursday, September 18, 2014 9:52 AM EST
The average small cap score is 51.24 this week, below the four week moving average score of 52.96. The average small cap stock is trading -26.83% below its 52 week high, -2.81% below its 200 dma, and has 8.37 days to cover held short.
In this article: CBK, EVC, ANAC, ARNA, BEAT, GIGM, INFN, AVID, FINL, CORT
Read
Orexigen Received The FDA's Approval For Contrave Yet Questions Remain
Article By: Dr. Hung Tran Thursday, September 11, 2014 6:33 PM EST
The FDA has approved Orexigen Therapeutics' (OREX) weight-management drug, Contrave. But is it a buy when similar products such as ARNA's Belviq, GSSK's Orlistat and VVUS's Qsymia – been unable to create traction in sales?
In this article: GSK, ARNA, OREX, VVUS
Read
1 to 16 of 24 Posts
1 2